Lantern Pharma (NASDAQ:LTRN) Posts Earnings Results, Misses Expectations By $0.03 EPS

Lantern Pharma (NASDAQ:LTRN) released its quarterly earnings data on Thursday. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03), Zacks reports.

Lantern Pharma Price Performance

Shares of NASDAQ:LTRN opened at $3.55 on Friday. The business has a 50-day moving average of $4.26 and a two-hundred day moving average of $3.78. The firm has a market capitalization of $38.29 million, a PE ratio of -1.99 and a beta of 1.64. Lantern Pharma has a 12 month low of $2.79 and a 12 month high of $9.96.

About Lantern Pharma

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.